Trial Profile
Phase II Trial of Everolimus (RAD001) in Relapsed/Refractory Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Oct 2019
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Leukaemia; Lymphoma; Lymphoproliferative disorders; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- 11 Oct 2019 Status changed from active, no longer recruiting to completed.
- 16 Oct 2018 Planned End Date changed from 1 Jan 2015 to 1 Dec 2020.
- 16 Oct 2018 Status has been changed to active, no longer recruiting.